The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Clinical development of curcumin in neurodegenerative disease
Open accessAbstract
Curcumin, a polyphenolic antioxidant derived from the turmeric root has undergone extensive preclinical development, showing remarkable efficacy in wound repair, cancer and inflammatory disorders. This review addresses the rationale for its use in neurodegenerative disease, particularly Alzheimer's disease. Curcumin is a pleiotropic molecule, which not only directly binds to and limits aggregation of the β-sheet conformations of amyloid characteristic of many neurodegenerative diseases but also restores homeostasis of the inflammatory system, boosts the heat shock system to enhance clearance of toxic aggregates, scavenges free radicals, chelates iron and induces anti-oxidant response elements. Although curcumin corrects dysregulation of multiple pathways, it may exert many effects via a few molecular targets. Pharmaceutical development of natural compounds like curcumin and synthetic derivatives have strong scientific rationale, but will require overcoming various hurdles including; high cost of trials, concern about profitability and misconceptions about drug specificity, stability, and bioavailability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two phase II trials151,152 in patients with AD, curcumin had no effect on cognition or CSF biomarkers149, and a third study in patients with MCI was terminated153.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Self-citationInfluence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers
Guido, S., Joy, D. C., Joseph, T., Majeed, M. A., Rajendran, R., & Srinivas, P. (1998) · Planta Medica · doi:10.1055/s-2006-957450 · Cited by 1,976
CURCUMIN: THE INDIAN SOLID GOLD
Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007) · Springer eBooks · doi:10.1007/978-0-387-46401-5_1 · Cited by 1,740
Stability of curcumin in buffer solutions and characterization of its degradation products
Wang, Y., Pan, M., Cheng, A., Lin, L., Ho, Y., Hsieh, C., & Lin, J. (1997) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(96)02024-9 · Cited by 1,709
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Self-citationDose escalation of a curcuminoid formulation
Lao, C. D., Ruffin, M. T., Normolle, D. P., Heath, D. D., Murray, S. I., Bailey, J. M., Boggs, M. E., Crowell, J. A., Rock, C. L., & Brenner, D. E. (2006) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-6-10 · Cited by 1,400
Activation of Transcription Factor NF-κB Is Suppressed by Curcumin (Diferuloylmethane)
Singh, S., & Aggarwal, B. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.24995 · Cited by 1,399
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Research works printed but not linked: 11
- Murugaiyah V, 2015, Neurochem Int
- Hickey MA, 2005, Soc Neurosci, 31, 90
- Xu YX, Hematopathol Mol Hematol 1997, 11, 49
- Cho JW, 2007, Int J Mol Med, 19, 469
- Huang MT, 1991, Cancer Res, 51, 813
- Soudamini KK, Indian J Physiol Pharmacol 1992, 36, 239
- Soni KB, 1992, Indian J Physiol Pharmacol, 36, 273
- Chen-Roetling J, 2015, 46, 1093
- Barone E, 2015, Neurobiol Dis
- National Toxicology P, 1993, Natl Toxicol Program Tech Rep Ser, 427, 1
- Cox KH, 2014, J Psychopharmacol
Cited by
Sorted by citations
Items 101–101 of 101
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021) · Antioxidants · doi:10.3390/antiox10101584 · Cited by 11
Metadata
- Authors
- Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A.
- Affiliations
- VA Greater Los Angeles Healthcare System (US)
- University of California, Los Angeles (US)
- Corresponding author
- Frautschy, Sally A
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2015-06-02
- Volume
- 15
- Issue
- 6
- Pages
- 629-637
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- PMC
- PMC6800094
- OpenAlex
- W1877722768
- Cited by
- 179
- References
- 101
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 18 · 2023: 16 · 2022: 12 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 20 · 2017: 20 · 2016: 11 · 2015: 3
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Review of Neurotherapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01 RX000669, I01 BX001257)
- National Institute on Aging (U01AG028583, R01AG021975)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Keywords
- curcumin, neurodegenerative diseases, Alzheimer's disease, amyloid fibril formation, anti-inflammatory activity, heat shock response, antioxidant activity, iron chelation, drug development, bioavailability, natural product derivatives
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Brain, Curcumin, Humans, Models, Biological, Retina, Amyloid beta-Peptides, tau Proteins, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
